glp-1 obesity drug news today september 15 2025 Oral Drugs Market Size and Forecast 2035 The first of three of
Description
Clinical validation is sparse, particularly for cancer pain and neuropathic pain
Worsening markers at any point should prompt reconsideration of the current approach
They do it because they are caught in what we call the Price-Safety Trap
Data from January 2021 through May 2023 Source: IQVIA LAAD pharmacy and medical claims
Studied together, the pairing has shown meaningful improvements in HbA1c, in insulin resistance markers such as HOMA-IR, and in fat mass over roughly 52 weeks of therapy, which makes it one of the best-established and lowest-risk combinations in modern diabetes care [4]
[DOI] [PMC free article] [PubMed] [Google Scholar] [13].Ussher JR, Drucker DJ
